Breaking News Instant updates and real-time market news.

NVCN

Neovasc

$3.72

0.17 (4.79%)

07:18
10/22/19
10/22
07:18
10/22/19
07:18

Neovasc announces multiple presentations featuring Neovasc Reducer

Neovasc announced that the Neovasc Reducer was featured in multiple presentations during the symposium "A Proven Evidence-based therapy when Angina Persists", held this month at the National Congress of the Italian Society of Interventional Cardiology in Milan, Italy. The highlights showed that 50% of the patients improved by 2 CCS Classes or more while 83% of patients improved by 1 CCS Class or more. Seventeen percent did not respond to the therapy. Additionally, the average CCS score decreased from 3.2 to 1.7. In selected presentations: Prof Shmuel Banai, Director, Division of Cardiology Tel-Aviv Medical Center, and Neovasc Medical Director, presented the history and rationale of coronary sinus narrowing for the treatment of angina. In 1948, American Cardiac Surgeon, Claude Schaffer Beck, developed an effective treatment for patients with disabling angina by creating a surgical narrowing of the coronary sinus. Between the years 1948 to 1964 Dr. Beck successfully used this procedure on more than 1,000 patients with coronary heart disease. In 1952, Dr. Beck became the first to receive the title of professor of cardiovascular surgery in the United States. More recently, Neovasc developed non-surgical methods to narrow the coronary sinus in Europe and Canada. These methods proved effective, enhancing blood supply to the ischemic heart, increasing quality of life and protecting the heart while reducing infarct size. Pr. Sergio Berti, Fondazione Toscana G. Monasterio, based on recent survey data of clinical cardiologists in the Milan area, reinforced that many patients suffer from angina despite optimal therapy. The clinical cardiologists polled estimate that as many as 12% of their angina patients are refractory to currently available therapies. On average, these physicians each had 20 such patients, of which approximately 50% were not satisfied with their current therapy. Physicians confirmed they would likely have sent these patients for a definitive interventional treatment, if they were aware of such a therapy. The conclusion of the survey was that there are still many patients with refractory angina, who are not satisfied with their quality of life or their current therapy, and who could potentially benefit from the Reducer. These leading cardiologists reinforced that the suffering of patients has a significant impact on their everyday life. As a measure of that, these patients on average return for a consultation on a monthly basis. Dr. Francesco Giannini, GVM Care & Research Maria Cecilia Hospital - Cotignola, reviewed the technical and procedural aspect of the Reducer Therapy. During his presentation, Dr. Giannini reinforced the strong safety profile of the procedure. On behalf of the investigators, Dr. Gianpiero D'Amico, University of Padua, presented the Italian Society of Interventional Cardiology Multi-Center study on the "Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina." One hundred eighty three patients suffering from severe refractory angina were treated with coronary sinus narrowing by Reducer implantation in 16 medical centers across Italy. Presented data demonstrated a 98% technical success rate. Efficacy data at median follow-up of 564 days showed significant improvements in angina severity with minimal rates of complications. Results, based on the Canadian Cardiovascular Society Class, showed that 50% of the patients improved by 2 CCS Classes or more, 83% of patients improved by 1 CCS Class or more and 17% did not respond to the therapy. The average CCS score decreased from 3.2 to 1.7. Quality of life as assessed by the Seattle Angina Questionnaire also improved significantly across all 5 domains. Data comparing the CCS Class improvement results of the Italian registry to seven other previously published Reducer studies demonstrated consistent results across all studies. Finally, the current President of GISE, Pr. Giuseppe Tarantini, University of Padua, reinforced the importance of the new European Society of Cardiology guidelines for the Reducer Therapy and the importance of this therapy for patients who currently have few treatment options

NVCN Neovasc
$3.72

0.17 (4.79%)

03/22/19
ADAM
03/22/19
NO CHANGE
Target $1.1
ADAM
Buy
Neovasc court win in Germany removes overhang, says Canaccord
Canaccord analyst Jason Mills said the ruling yesterday from a German court in dismissing the claim to co-inventorship of the Tiara device made by Edwards Lifesciences' (EW) CardiAQ removes a litigation overhang for Neovasc (NVCN). Mills continues to view Neovasc as an "attractive, albeit admittedly risky," play on the Transcatheter Mitral Valve Repair sector and keeps a Buy rating and $1.10 price target on the shares.

TODAY'S FREE FLY STORIES

TXMD

TherapeuticsMD

$2.39

0.01 (0.42%)

, AMRX

Amneal Pharmaceuticals

$5.15

1.66 (47.63%)

13:59
12/12/19
12/12
13:59
12/12/19
13:59
Recommendations
TherapeuticsMD, Amneal Pharmaceuticals, Merck analyst commentary  »

Stifel says…

TXMD

TherapeuticsMD

$2.39

0.01 (0.42%)

AMRX

Amneal Pharmaceuticals

$5.15

1.66 (47.63%)

MRK

Merck

$89.27

0.31 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

HURN

Huron

$69.15

0.23 (0.33%)

13:57
12/12/19
12/12
13:57
12/12/19
13:57
Conference/Events
Huron management to meet with Benchmark »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

13:55
12/12/19
12/12
13:55
12/12/19
13:55
Conference/Events
The FDIC to hold a Board Meeting »

Board of Directors…

MLNT

Melinta Therapeutics

$1.71

0.15 (9.62%)

13:48
12/12/19
12/12
13:48
12/12/19
13:48
Hot Stocks
FDA approves Melinta Therapeutics sNDA for Orbactiv for injection »

A letter posted by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$122.30

-0.08 (-0.07%)

13:45
12/12/19
12/12
13:45
12/12/19
13:45
Options
TakeTwo Interactive Software call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

KW

Kennedy Wilson

$22.26

-0.25 (-1.11%)

13:44
12/12/19
12/12
13:44
12/12/19
13:44
Hot Stocks
Kennedy Wilson raises quarterly dividend 5% to 22c per share »

Kennedy Wilson announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

SPY

SPDR S&P 500 ETF Trust

$316.35

1.94 (0.62%)

, SPX

S&P 500

$0.00

(0.00%)

13:38
12/12/19
12/12
13:38
12/12/19
13:38
Periodicals
WH Press Secretary says President to hold trade meeting at 2:30, CNBC reports »

CNBC political reporter…

SPY

SPDR S&P 500 ETF Trust

$316.35

1.94 (0.62%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$67.62

0.48 (0.71%)

13:36
12/12/19
12/12
13:36
12/12/19
13:36
Periodicals
PrEP4All says USPTO adviser showed 'bias' in favor of Gilead, STAT reports »

An AIDS activist group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$8.98

0.01 (0.11%)

13:35
12/12/19
12/12
13:35
12/12/19
13:35
Options
Barclays put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$11.37

0.385 (3.51%)

13:20
12/12/19
12/12
13:20
12/12/19
13:20
Options
Largest trade of the day is a Jan 2021 GE 1x3 totalling 108K contracts »

Largest trade of the day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

13:20
12/12/19
12/12
13:20
12/12/19
13:20
General news
Treasury's $16 B 30-year bond reopening was very, very well received »

Treasury's $16 B…

HIIQ

Health Insurance Innovations

$19.23

0.88 (4.80%)

13:17
12/12/19
12/12
13:17
12/12/19
13:17
Recommendations
Health Insurance Innovations analyst commentary  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/12/19
12/12
13:17
12/12/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/12/19
12/12
13:16
12/12/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:08
12/12/19
12/12
13:08
12/12/19
13:08
General news
30-Yr Bond Auction Coupon Rate data reported »

30-Yr Bond Auction Coupon…

13:08
12/12/19
12/12
13:08
12/12/19
13:08
General news
30-Yr Bond Auction Total Amount data reported »

30-Yr Bond Auction Total…

INSG

Inseego

$7.67

0.24 (3.23%)

13:05
12/12/19
12/12
13:05
12/12/19
13:05
Options
Inseego call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$5.16

1.675 (48.06%)

13:00
12/12/19
12/12
13:00
12/12/19
13:00
Recommendations
Amneal Pharmaceuticals analyst commentary  »

Amneal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$219.47

-0.59 (-0.27%)

, PTI

Proteostasis

$4.01

-0.23 (-5.42%)

12:55
12/12/19
12/12
12:55
12/12/19
12:55
Conference/Events
Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call »

Biotechnology Analysts…

VRTX

Vertex

$219.47

-0.59 (-0.27%)

PTI

Proteostasis

$4.01

-0.23 (-5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Mar

ADBE

Adobe

$304.30

0.55 (0.18%)

, AVGO

Broadcom

$324.00

4.14 (1.29%)

12:53
12/12/19
12/12
12:53
12/12/19
12:53
Earnings
Notable companies reporting after market close »

Notable companies…

ADBE

Adobe

$304.30

0.55 (0.18%)

AVGO

Broadcom

$324.00

4.14 (1.29%)

COST

Costco

$295.82

0.6 (0.20%)

ORCL

Oracle

$56.16

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 23

    Jan

12:50
12/12/19
12/12
12:50
12/12/19
12:50
General news
U.S. Household net worth rose »

U.S. Household net worth…

12:50
12/12/19
12/12
12:50
12/12/19
12:50
General news
Treasury Action: yields remain near their highs of the sessio »

Treasury Action: yields…

CC

Chemours

$17.55

0.955 (5.75%)

12:45
12/12/19
12/12
12:45
12/12/19
12:45
Options
Chemours call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:41
12/12/19
12/12
12:41
12/12/19
12:41
Hot Stocks
Breaking Hot Stocks news story  »

Liberty TripAdvisor…

12:36
12/12/19
12/12
12:36
12/12/19
12:36
Hot Stocks
Breaking Hot Stocks news story  »

Liberty TripAdvisor…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.